Butorphanol
Back to search| Scientific Name: | Butorphanol |
| Brand Name: | Stadol |
| Company Owner: | Bedford laboratories div ben venue laboratories inc, Claris lifesciences ltd, Hikma farmaceutica (portugal) sa, Hikma farmaceutica sa, Hospira inc, Apothecon inc div bristol myers squibb, Mylan pharmaceuticals inc, Novex pharma, Roxane laboratories inc, Bristol myers squibb co pharmaceutical research institute |
| Mechanism Of Action | The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system) . The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Butorphanol is a mixed agonist-antagonist that exerts antagonistic or partially antagonistic effects at mu opiate receptor sites, but is thought to exert its agonistic effects principally at the kappa and sigma opiate receptors. |
| Description of the Drug: | Butorphanol is an opioid agonist-antagonist used to treat moderate to severe pain. |
| Protein Data Bank: | Not Available |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00611
